

Women's and Children
Paediatric Neurosciences
Multiple Sclerosis Management Service for Children

170019/S

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
MSM01	Proportion of patients discussed by core members of the Hub Lead Centre Multi-Disciplinary Team (MDT) including MS Lead Clinician within 7 days from receipt of referral	For those patients in the denominator, the number of patients discussed within 7 days from receipt of referral	The total number of patients discussed by core members of the Hub Lead Centre MDT including MS Lead Clinician in the reporting period	Annual	Annual	Provider	Provider		Note: Include referrals at Hub Lead Centre only as per the Service Specification, the MDT quorum will be made up of the following core members, or their cover: paediatric neurologist with expertise in paediatric MS; MS Clinical Nurse Specialists; neuroradiologist; and clinical psychologist	N/A	N/A	N/A	Apr-22 - Mar-23
MSM02	Proportion of known patients physically assessed within 48 hour following direct liaison and discussion between the local unit and the Hub Lead Centre	Of those in the denominator, the number of patients assessed within 48 hours following direct liaison and discussion between the local unit and the Hub Lead Centre	The total number of known patients physically assessed following direct liaison and discussion between the local unit and the Hub Lead Centre in the reporting period	Annual	Annual	Provider	Provider		Note: Include referrals at Hub Lead Centre only Include direct liaison between the local unit and the Hub Lead Centre Include known patients only i.e where the outcome is known	N/A	N/A	N/A	Apr-22 - Mar-23
MSM03	Proportion of patients initiating therapy that have been discussed by the Hub Lead Centre Multi-Disciplinary Team (MDT) with documentation of the recommendations / outcomes provided to the patient and the General Practitioner (GP)	For those patients in the denominator, the number of patients whose MDT recommendations / outcomes are documented and provided to both patient and GP	The total number of patients discussed at Hub Lead Centre MDT in the reporting period	Annual	Annual	Provider	Provider		Note: Include referrals at Hub Lead Centre only	N/A	N/A	N/A	Apr-22 - Mar-23
MSM04	Proportion of patients starting the first dose of disease modifying therapy within 4 weeks of the agreement of the treatment plan, as defined in the service specification	Of those in denominator, the number of patients starting therapy within 4 weeks of the agreement of the treatment plan	The total number of patients starting disease modifying therapy in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
MSM06	Proportion of patients achieving a slowing in progression of disease using Annualised Relapse Rate (ARR)	Of those in the denominator, the number of patients who have seen a reduction in relapse rate using ARR	The total number of patients, in the reporting period, who have been in treatment for at least a year (12 months)	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
MSM06a	Proportion of patients achieving a slowing in progression of disease using No Evidence of Disease Activity (NEDA) - no evidence of relapse	Of those in the denominator, the number of patients who have achieved disease remission using NEDA - no evidence of relapse	The total number of patients, in the reporting period, who have been in treatment for at least a year (12 months)	Annual	Annual	Provider	Provider		Note: Remission' as defined by No Evidence of Disease Activity (NEDA): no evidence of relapse	N/A	N/A	N/A	Apr-22 - Mar-23
MSM06b	Proportion of patients achieving a slowing in progression of disease using No Evidence of Disease Activity (NEDA) - no evidence of relapse and no MRI activity	Of those in the denominator, the number of patients who have achieved disease remission using NEDA - no MRI activity	The total number of patients, in the reporting period, who have been in treatment for at least a year (12 months)	Annual	Annual	Provider	Provider		Note: Remission' as defined by No Evidence of Disease Activity (NEDA): no evidence of relapse and no MRI activity	N/A	N/A	N/A	Apr-22 - Mar-23
MSM06c	Proportion of patients achieving a slowing in progression of disease using No Evidence of Disease Activity (NEDA) - no evidence of relapse, no MRI activity and no evidence of disease progression	Of those in the denominator, the number of patients who have achieved disease remission using NEDA - no evidence of disease progression	The total number of patients, in the reporting period, who have been in treatment for at least a year (12 months)	Annual	Annual	Provider	Provider		Note: Remission' as defined by No Evidence of Disease Activity (NEDA): no evidence of relapse, no MRI activity and no evidence of disease progression	N/A	N/A	N/A	Apr-22 - Mar-23
MSM07	Proportion of eligible and consented patients who are recruited to a clinical trial	Of those in the denominator, the number of patients recruited to a clinical trial	The total number of eligible consented patients on caseload in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23

Women's and Children
 Paediatric Neurosciences
 Multiple Sclerosis Management Service for Children

170019/S

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
MSM08	Proportion of medication errors resulting in significant harm to patients as defined by the Common Terminology Criteria for Adverse Events v3.0 (CTCAE)	Of those in the denominator, the number of errors reported that resulted in significant harm to the patient as defined by CTCAE	The total number of all patients on medication in the reporting period	Annual	Annual	Provider	Provider		Include CTCAE category 3 or higher.	N/A	N/A	N/A	Apr-22 - Mar-23